Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)

This study has been completed.
Sponsor:
Collaborator:
Mainz University
Information provided by (Responsible Party):
Beckman Laser Institute and Medical Center, University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00610402
First received: January 25, 2008
Last updated: June 6, 2015
Last verified: June 2015
  Purpose

Sturge-Weber Syndrome (SWS) is a neurological disorder characterized at birth by seizures and a large port-wine stain birthmark on the forehead and upper eyelid of one side of the face. SWS is also accompanied by an increased pressure within the eye (glaucoma) which can develop very early in life.

Glaucoma represents a group of ocular disorders that are characterized by the loss of retinal ganglion cells and their axons, damage to the optic nerve, and gradual loss of visual field. Recently, several studies provided evidence that there is a potential role of the immune system in the pathogenesis of glaucoma.

These findings suggest that there might be changes in systemic humoral immunity possibly underlying the optic neuropathy in at least some glaucoma patients.


Condition Intervention
Sturge - Weber Syndrome (SWS)
Other: blood sample tear drop sample

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)

Resource links provided by NLM:


Further study details as provided by University of California, Irvine:

Biospecimen Retention:   Samples Without DNA

blood sample tear drop sample


Enrollment: 57
Study Start Date: July 2007
Study Completion Date: June 2008
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
blood sample tear drop sample
blood sample tear drop sample
Other: blood sample tear drop sample
blood sample tear drop sample

Detailed Description:

The ocular antibody profile in patients with SWS is unknown.The researchers want to study on blood and tear drop samples from patients with SWS to determine the incidence of ocular antibodies in patients with this syndrome.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

community sample

Criteria

Inclusion Criteria:

  • Male and female volunteers with SWS of all ages

Exclusion Criteria:

  • Volunteers without SWS
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00610402

Locations
United States, California
Beckman Laser Institute Medical clinic
Irvine, California, United States, 92612
Sponsors and Collaborators
University of California, Irvine
Mainz University
Investigators
Principal Investigator: John S Nelson, M.D,PhD Beckman Laser Institute University of California Irvine
  More Information

No publications provided

Responsible Party: Beckman Laser Institute and Medical Center, J.S.Nelson, MD,PhD,Professor of Surgery and Biomedical Engineering, University of California, Irvine
ClinicalTrials.gov Identifier: NCT00610402     History of Changes
Other Study ID Numbers: NIH-LAMMP-2006-5691
Study First Received: January 25, 2008
Last Updated: June 6, 2015
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Klippel-Trenaunay-Weber Syndrome
Sturge-Weber Syndrome
Brain Stem Infarctions
Syndrome
Angiomatosis
Brain Diseases
Brain Infarction
Brain Ischemia
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Disease
Hemangioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Vascular Tissue
Nervous System Diseases
Neurocutaneous Syndromes
Pathologic Processes
Stroke
Vascular Diseases

ClinicalTrials.gov processed this record on July 01, 2015